India's Dr Lal Path Labs climbs on Q2 profit rise

Dr. Lal PathLabs

03/11/2025 06:07

** Dr Lal Path Labs DLPA.NS rises ~4% to 3,258 rupees

** Diagnostics firm's Q2 consol net PAT rises 16.5% y/y, rev from ops up ~11% y/y

** ICICI Securities says co's Swasthfit segment continues to drive growth; adds co has multiple growth projects underway

** Emkay says co's margin performance continues to be robust

** Stock rated "buy" on avg; median PT is 3,378 rupees, per data compiled by LSEG

** YTD, DLPA up ~9%

 (Reporting by Komal Salecha)

 ((Komal@thomsonreuters.com;))